Triplet combo shows promise in early-phase trial for newly diagnosed MM
A phase 1/2 study showed that iberdomide, daratumumab, and dexamethasone (IBERDd) had a manageable safety profile when used in transplant-ineligible, newly diagnosed multiple
Multiple Myeloma News
SOHO 2025
Meetings / Conferences
News
Lymphoma
Indolent B-Cell Lymphomas
Poor outcomes in a subgroup of follicular lymphoma prompts need for personalized treatment approach
Prior studies have shown conflicting outcomes for patients with different follicular lymphoma (FL) grade subtypes. A recent study by Patrizia Mondello, MD, PhD